Articles related to HEMATOLOGY/ONCOLOGY

HBCLs, not-otherwise specified (NOS), are rare and heterogeneous; other than having germinal center B-cell phenotype, and in up to 45%, a single-hit MYC rearrangement, they have no unifying immunophenotypic or cytogenetic characteristics. This review discusses the current clinicopathologic concept of HGBL, NOS, and looks at potential future taxonomy enrichments based on emerging molecular diagnostics.

Over a 4-year period, 500 patients were distributed equally between the two regimens. Two-year OS, relapse rates, and non-relapse mortality were similar between the two regiments, indicating that the busulfan regimen is non-inferior to the traditional TBI regimen.

This review summarizes the clinical presentation, workup, staging, and recent advancements in the treatment of PCNSL. Although treatment advances include the use of BTK inhibitors and immunomodulators, relapse is common and 5-year survival is 40% or lower. Thus, accurate early diagnosis and initiation of treatment is time sensitive for optimal neurologic recovery and disease control.

The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) regimen has undergone many modifications to make administration more palatable and user-friendly for patients and physicians in community and academic settings, including refinements to avoid complications and reduce adverse events. Dr. Elias Jabbour of MD Anderson Cancer Center reviews a number of these modifications in this interview.

In patients with advanced-stage, untreated follicular lymphoma (FL), the RELEVANCE trial demonstrated that rituximab plus chemotherapy (R-chemo) and lenalidomide plus rituximab (R2) had comparable efficacy (FL). After six years of follow-up, a report on the second interim analysis of the RELEVANCE experiment is presented here.

The differences between bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy, the side effects of bispecific antibodies, how the antibodies may address unmet needs in lymphoma, and a few other observations are discussed in this interview with Dr. John N. Allan, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York.